VAVincent Allain

Vincent Allain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vincent Allain has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Targeted integration of a chimeric antigen receptor into natural killer cells (CAR-NK) : specific optimization of the transgene design and the integration loci

    by Vincent Allain

    Cellules natural killer modifiées génétiquement pour exprimer un récepteur à l'antigène chimérique (CAR-NK) : optimisation spécifique du design des transgènes et des loci d'intégration: L'introduction des cellules CAR-T a révolutionné la prise en charge clinique de certains cancers, en particulier des hémopathies malignes. Plus récemment, les cellules Natural Killers (NK), qui présentent une activité antitumorale innée, sont apparus comme une plateforme cellulaire alternative pour le développement de nouvelles cellules immunitaires exprimant un CAR. Les CAR-NK pourraient en théorie surmonter certaines difficultés rencontrées avec les CAR-T, en particulier en contexte allogénique. Mais malgré de premiers succès cliniques (Liu et al., NEJM, 2020), les CAR-NK restent une approche moins mature que les CAR-T, dont l'optimisation se heurte à un ensemble de problématiques à la fois techniques et biologiques. Notre hypothèse est que les CAR-NK pourraient bénéficier des techniques modernes d'édition génique, en particulier de l'intégration ciblée du transgène CAR dans un locus cible en comparaison aux vecteurs rétroviraux classiquement utilisés résultant en une intégration semi-aléatoire du transgène. Cette approche s'avère très bénéfique dans le contexte des cellules CAR-T et du locus du TCR alpha (Eyquem et al., Nature, 2017). Dans une première partie, nous décrivons l'optimisation d'un protocole d'édition génique adapté aux cellules NK humaines primaires. Nous établissons une stratégie robuste de Knock-out et de Knock-in reposant sur l'utilisation de la technologie CRISPR/Cas9 en combinaison avec l'utilisation de particules virales (AAV6) pour la délivrance du transgène. Cette technique est ensuite appliquée à la génération de CAR-NK. L'expression ubiquitaire et constitutive forte de la Beta-2 microglobuline (B2M) en fait un locus prometteur pour l'intégration d'un CAR sous contrôle de son promoteur endogène. Le transgène est conçu pour assurer le sauvetage du gène B2M lors du Knock-in, permettant le maintien d'une expression intermédiaire de B2M. Cette stratégie permet d'obtenir des CAR-NK présentant un fort niveau d'expression du CAR, plus homogène qu'avec une approche rétrovirale, et offre une protection contre l'attaque fratricide secondaire à la perte complète d'expression des molécules du HLA de classe I résultant du knock-out de B2M. Fonctionnellement, nous montrons que les cellules B2M CAR-NK ainsi générées présentent une cytotoxicité accrue in vitro dans différents modèles de tumeurs CD19+ en comparaison aux cellules NK WT. Néanmoins, malgré leurs caractéristiques avantageuses, les cellules B2M CAR-NK se révèlent inferieures à des CAR-NK générés par approche rétrovirale, en particulier dans un modèle tumoral murin de xénogreffe de tumeur ovarienne humaine. Ces observations nous conduisent, dans une seconde partie, à étendre cette approche en explorant un ensemble de loci alternatifs, pertinents dans la physiologie des cellules NK (récepteurs activateurs ou inhibiteurs), pour y intégrer un CAR. Pour les récepteurs activateurs, le transgène est conçu pour utiliser le promoteur endogène du gène cible et maintenir l'expression du locus cible, alors que dans le cas des récepteurs inhibiteurs, le transgène est placé sous la régulation d'un promoteur exogène aboutissant à la perte d'expression du gène ciblé. En suivant cette approche, nous identifions des loci d'intégration supérieurs à B2M dans des expériences de cytotoxicité in vitro, dont nous décrivons l'efficacité in vivo dans le modèle murin préalablement décrit. Par la suite, TIGIT est choisi comme locus de référence pour comparer différentes variations du design du transgène CAR, comme l'utilisation de multiples promoteurs exogènes permettant de moduler le niveau d'expression du CAR, ou l'effet de l'altération des motifs ITAM du domaine CD3z du CAR. En conclusion, nos résultats démontrent l'intérêt de l'édition génique de cellules NK primaires dans le développement de nouvelles générations de CAR-NK. Les techniques développées dans cette thèse pourraient aussi s'avérer de puissants outils pour approfondir la connaissance de la biologie des cellules NK.

  • Open Access

    Harnessing HLA Divergence for Improved Donor Selection in Haploidentical Haematopoietic Stem Cell Transplantation

    by Debora Jorge Cordeiro, Juliette Villemonteix, Alienor Xhaard, Ophélie Ferrary, William Dartois, Bruno A. Lima, Laurie Toullec, Regis Peffault de Latour, Sophie Caillat‐Zucman, Vincent Allain

    Haploidentical haematopoietic stem cell transplantation (haplo‐HSCT) with post‐transplant cyclophosphamide (PTCy)‐based graft‐versus‐host disease (GVHD) prophylaxis is commonly used in patients without a fully matched donor. HLA evolutionary divergence (HED), a surrogate for the diversity of the immunopeptidome, can predict HLA‐matched HSCT outcomes. Because of the peculiarities of HED measurement in haplo‐HSCT, we designed a new HED D‐>R metric to proxy the fraction of the recipient‐specific immunopeptidome not recognised as self by the haplo‐identical donor, and evaluated its predictive value on haplo‐HSCT outcomes with the aim of providing help in choosing the best donor. We retrospectively studied 104 patients who underwent PTCy haplo‐HSCT for haematological malignancy and calculated per‐locus and per‐class HED in the recipient (HED R ), the donor (HED D ), across mismatched haplotypes (HED MM ) as well as HED D‐>R . Patients with low class 1 HED R had worse OS (hazard ratio (HR) 2.16, 95% confidence intervals (CI) 1.06–4.40, p = 0.033), whereas no significant impact of HED D or HED MM at any HLA locus was observed. Moreover, in multivariate analysis of patients surviving at least 100 days, low class 1 HED D‐>R was associated with inferior OS (HR 2.67, 95% CI 1.13–6.28; p = 0.025). In addition to strengthening the impact of recipient class 1 HED on HSCT outcomes regardless of donor type, our results suggest that our novel, publicly available, HED D‐>R metric could help select the most appropriate donor among haploidentical candidates.


  • Open Access

    Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function

    by Vincent Allain, Allison G. Rothrock, Pierre-Louis Bernard, William A. Nyberg, Alexis Talbot, Joseph J. Muldoon, Jing-Yi Chung, Angela To, Christopher R. Chang, Gabriella R. Kimmerly, et al.

    Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified TIGIT as an ideal locus that supports strong CAR expression and anti-tumor function. This genome engineering framework, which leverages multiple, complementary and precisely controlled genetic edits, can support the rational design of future NK-cell therapies tailored to overcome cell-intrinsic limitations and tumor-specific barriers.

  • Open Access

    Donor HLA-DQ genetic and functional divergence affect the control of BK polyoma virus infection after kidney transplantation

    by Mathieu F. Chevalier, Vincent Allain, Julien Gras, Julien Racle, Juliette Villemonteix, Gillian Divard, Linda Feghoul, Constance Delaugerre, Jean-Michel Molina, Jean-Luc Taupin, et al.

    BK polyomavirus (BKPyV) infection remains a major concern after kidney transplantation, increasing the risk of graft loss in the absence of specific antiviral agent now available. Here, we investigated the impact of HLA diversity on the control of posttransplant BKPyV replication. High HLA evolutionary divergence (HED) at the DQ locus in the donor was an independent predictor of BKPyV-free outcome. More generally, we highlighted the protective effect of highly divergent pairs of HLA-DQ heterodimers corresponding to heterozygous HLA-DQα01/non-DQα01 combinations. We then defined a functional divergence metrics assessed by the similarity of peptide-binding motifs between pairs of HLA-DQ molecules. Greater functional divergence correlated with the size of the BKPyV-derived DQ-bound immunopeptidome and a lower risk of BKPyV reactivation, thus providing a molecular basis for the observed genetic differences. Together, these data provide evidence for a direct link between donor HLA-DQ genetic and functional divergence, diversity of the DQ-bound immunopeptidome, and control of viral infection, likely reflecting stronger antiviral T cell responses.


  • SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy

    by Alberto J Millan, Vincent Allain, Indrani Nayak, Jeremy B Libang, Lilian M Quijada-Madrid, Janice S Arakawa-Hoyt, Gabriella Ureno, Allison Grace Rothrock, Avishai Shemesh, Oscar A Aguilar, et al.

    Natural killer (NK) cells express activating receptors that signal through ITAM (immunoreceptor tyrosine-based activation motif)-bearing adapter proteins. The phosphorylation of each ITAM creates binding sites for SYK and ZAP70 protein tyrosine kinases to propagate downstream signaling including the induction of Ca2+ influx. While all immature and mature human NK cells coexpress SYK and ZAP70, clonally driven memory or adaptive NK cells can methylate SYK genes, and signaling is mediated exclusively using ZAP70. Here, we examined the role of SYK and ZAP70 in a clonal human NK cell line KHYG1 by CRISPR-based deletion using a combination of experiments and mechanistic computational modeling. Elimination of SYK resulted in more robust Ca2+ influx after crosslinking of the CD16 and NKp30 receptors and enhanced phosphorylation of downstream proteins, whereas ZAP70 deletion diminished these responses. By contrast, ZAP70 depletion increased proliferation of the NK cells. As immature T cells express both SYK and ZAP70 and mature T cells often express only ZAP70, we transduced the human Jurkat cell line with SYK and found that expression of SYK increased proliferation but diminished T cell receptor–induced Ca2+ flux and activation. We performed transcriptional analysis of the matched sets of variant Jurkat and KHYG1 cells and observed profound alterations caused by SYK expression. As depletion of SYK in NK cells increased their activation, primary human NK cells were transduced with a CD19-targeting chimeric antigen receptor and were CRISPR edited to ablate SYK or ZAP70. Deletion of SYK resulted in more robust cytotoxic activity and cytokine production, providing a new therapeutic strategy of NK cell engineering for cancer immunotherapy.


  • Open Access

    HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

    by Sophie Le Grand, Juliette Villemonteix, Etienne Daguindau, Marylise Fort, Sophie Caillat‐Zucman, Vincent Allain, Anne Dormoy, Veronique De Mas, Eric Delabesse, Christian Recher, et al.

    Donor lymphocyte infusion (DLI) prevents acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) relapses following hematopoietic stem cell transplantation. Given the life‐threatening toxicities such as graft versus host disease (GVHD), the identification of variables associated with response without toxicities is warranted. We hypothesized that HLA evolutionary divergence (HED), defined by the diversity between two given alleles of the same HLA gene, may be such a factor. A retrospective multicenter case‐control study was conducted to evaluate the outcomes of pre‐emptive (preDLI) and prophylactic DLI (proDLI) regarding their HED score, in AML or MDS patients. DLI‐treated patients were matched with controls (1:2 matched) from French transplantation centers according to hospital, hemopathy, donor type, and risk classification. In total, 201 patients were included ( N = 147 in the preDLI group, N = 54 in the proDLI group). Relapse‐free survival was significantly better in the preDLI group (hazard ratio [HR] = 0.23, 95% confidence interval [CI]: 0.14–0.55, p < 0.001) than in controls. However, this benefit was offset by a higher incidence of severe GVHD (HR = 4.88, 95% CI: 2.30–10.32, p < 0.001). HED A, B, C, DQA1, DQB1, DPB1, and DRB1 were calculated for 65 DLI‐treated patients. High‐class II HED was significantly associated with higher GVHD and relapse‐free survival (GRFS, HR = 0.33, 95% CI: 0.20–0.77, p = 0.005). Specific DQAB associations directly improved GRFS (HR = 0.23, 95% CI: 0.09–0.58, p = 0.004). In conclusion, screening the class II HED score identifies patients eligible for DLI treatment who will benefit the most from this strategy.


  • Open Access

    Spleen Tyrosine Kinase (SYK) negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy

    by Alberto J. Millan, Vincent Allain, Indrani Nayak, Oscar A. Aguilar, Janice S. Arakawa-Hoyt, Gabriella Ureno, Allison Grace Rothrock, Avishai Shemesh, Justin Eyquem, Jayajit Das, et al.

    NK cells express activating receptors that signal through ITAM-bearing adapter proteins. The phosphorylation of each ITAM creates binding sites for SYK and ZAP70 protein tyrosine kinases to propagate downstream signaling including the induction of Ca 2+ influx. While all immature and mature human NK cells co-express SYK and ZAP70, clonally driven memory or adaptive NK cells can methylate SYK genes and signaling is mediated exclusively using ZAP70. Here, we examined the role of SYK and ZAP70 in a clonal human NK cell line KHYG1 by CRISPR-based deletion using a combination of experiments and mechanistic computational modeling. Elimination of SYK resulted in more robust Ca ++ influx after cross-linking of the CD16 and NKp30 receptors and enhanced phosphorylation of downstream proteins, whereas ZAP70 deletion diminished these responses. By contrast, ZAP70 depletion increased proliferation of the NK cells. As immature T cells express both SYK and ZAP70 but mature T cells often express only ZAP70, we transduced the human Jurkat cell line with SYK and found that expression of SYK increased proliferation but diminished TCR-induced Ca 2+ flux and activation. We performed transcriptional analysis of the matched sets of variant Jurkat and KHYG1 cells and observed profound alterations caused by SYK expression. As depletion of SYK in NK cells increased their activation, primary human NK cells were transduced with a CD19-targeting CAR and were CRISPR edited to ablate SYK or ZAP70 . Deletion of SYK resulted in more robust cytotoxic activity and cytokine production, providing a new therapeutic strategy of NK cell engineering for cancer immunotherapy.


  • Open Access

    Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells

    by Brandon J. Sytsma, Vincent Allain, Struan Bourke, Fairuz Faizee, Mohsen Fathi, Rebecca Berdeaux, Leonardo M.R. Ferreira, W. Jared Brewer, Lian Li, Fong L. Pan, et al.

    Adoptive chimeric antigen receptor T-cell (CAR-T) therapy is transformative and approved for hematologic malignancies. It is also being developed for the treatment of solid tumors, autoimmune disorders, heart disease, and aging. Despite unprecedented clinical outcomes, CAR-T and other engineered cell therapies face a variety of manufacturing and safety challenges. Traditional methods, such as lentivirus transduction and electroporation, result in random integration or cause significant cellular damage, which can limit the safety and efficacy of engineered cell therapies. We present hydroporation as a gentle and effective alternative for intracellular delivery. Hydroporation resulted in 1.7- to 2-fold higher CAR-T yields compared to electroporation with superior cell viability and recovery. Hydroporated cells exhibited rapid proliferation, robust target cell lysis, and increased pro-inflammatory and regulatory cytokine secretion in addition to improved CAR-T yield by day 5 post-transfection. We demonstrate that scaled-up hydroporation can process 5 × 10 8 cells in less than 10 s, showcasing the platform as a viable solution for high-yield CAR-T manufacturing with the potential for improved therapeutic outcomes.


  • Two‐field resolution on‐call HLA typing for deceased donors using nanopore sequencing

    by Magali Devriese, Sephora Da Silva, Melchior Le Mene, Julien Rouquie, Vincent Allain, Libor Kolesar, Krisztina Rigo, Lisa E. Creary, Nina Lauterbach, Cedric Usureau, et al.

    The current practice of HLA genotyping in deceased donors poses challenges due to limited resolution within time constraints. Nevertheless, the assessment of compatibility between anti‐HLA sensitized recipients and mismatched donors remains a critical medical need, particularly when dealing with allele‐specific (second field genotyping level) donor‐specific antibodies. In this study, we present a customized protocol based on the NanoTYPE® HLA typing kit, employing the MinION® sequencer, which enables rapid HLA typing of deceased donors within a short timeframe of 3.75 h on average at a three‐field resolution with almost no residual ambiguities. Through a prospective real‐time analysis of HLA typing in 18 donors, we demonstrated the efficacy and precision of our nanopore‐based method in comparison to the conventional approach and without delaying organ allocation. Indeed, this duration was consistent with the deceased donor organ donation procedure leading to organ allocation via the French Biomedicine Agency. The improved resolution achieved with our protocol enhances the security of organ allocation, particularly benefiting highly sensitized recipients who often present intricate HLA antibody profiles. By overcoming technical challenges and providing comprehensive genotyping data, this approach holds the potential to significantly impact deceased donor HLA genotyping, thereby facilitating optimal organ allocation strategies.


  • Open Access

    Ultra-high efficiency T cell reprogramming at multiple loci with SEED-Selection

    by Christopher R. Chang, Vivasvan S. Vykunta, Daniel B. Goodman, Joseph J. Muldoon, William A. Nyberg, Chang Liu, Vincent Allain, Allison Rothrock, Charlotte H. Wang, Alexander Marson, et al.

    Multiplexed reprogramming of T cell specificity and function can generate powerful next-generation cellular therapies. However, current manufacturing methods produce heterogenous mixtures of partially engineered cells. Here, we develop a one-step process to enrich for unlabeled cells with knock-ins at multiple target loci using a family of repair templates named S ynthetic E xon/ E xpression Disruptors (SEEDs). SEED engineering associates transgene integration with the disruption of a paired endogenous surface protein, allowing non-modified and partially edited cells to be immunomagnetically depleted (SEED-Selection). We design SEEDs to fully reprogram three critical loci encoding T cell specificity, co-receptor expression, and MHC expression, with up to 98% purity after selection for individual modifications and up to 90% purity for six simultaneous edits (three knock-ins and three knockouts). These methods are simple, compatible with existing clinical manufacturing workflows, and can be readily adapted to other loci to facilitate production of complex gene-edited cell therapies.